Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Single-Blind Study to Evaluate the Pharmacokinetics, Biomarkers, Safety and Tolerability of STAT-205 in Adult Patients With Mild COVID 19 Who Are at High Risk of Disease Progression

Next Previous
X
Search
Trial Profile

Randomized, Single-Blind Study to Evaluate the Pharmacokinetics, Biomarkers, Safety and Tolerability of STAT-205 in Adult Patients With Mild COVID 19 Who Are at High Risk of Disease Progression

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Statera BioPharma

    • Most Recent Events

    • 02 Mar 2022 According to a Statera Biopharma media release, the Company expects to conclude enrollment during the third quarter and report topline results in the fourth quarter.
    • 02 Mar 2022 According to a Statera Biopharma media release, this study is halfway through its enrollment of 24 patients.
    • 20 Dec 2021 According to a Statera Biopharma media release, the first patient was dosed in this trial. The company expects preliminary trial results to be reported in 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top